Last close As at 05/08/2026
GBP1.20
▲ 0.50 (0.42%)
Market capitalisation
—
Research: Industrials
Epwin’s H119 update reiterated existing guidance. Markets remain soft but business improvement activities, including new facility and product development investment, are ongoing and should be reflected in earnings improvement. The company remains conservatively funded and in a good position to continue to develop. An excellent dividend yield and modest rating at an earnings low represent good entry points for investors.
Written by
Epwin Group |
Making progress in soft markets |
End H119 update |
Construction & materials |
12 August 2019 |
Share price performance
Business description
Next events
Analyst
Epwin Group is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||
Epwin’s H119 update reiterated existing guidance. Markets remain soft but business improvement activities, including new facility and product development investment, are ongoing and should be reflected in earnings improvement. The company remains conservatively funded and in a good position to continue to develop. An excellent dividend yield and modest rating at an earnings low represent good entry points for investors.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17** |
292.8 |
22.4 |
13.4 |
6.7 |
5.8 |
9.1 |
12/18 |
281.1 |
16.5 |
9.8 |
4.9 |
7.5 |
6.7 |
12/19e |
291.3 |
17.6 |
10.1 |
5.0 |
7.3 |
6.8 |
12/20e |
296.2 |
18.7 |
10.7 |
5.3 |
6.9 |
7.2 |
Note: *PBT and EPS (fully diluted) are normalised, excluding intangible amortisation and exceptionals. **Restated to exclude discontinued operations.
Progress in tough markets
H119 revenue was marginally ahead y-o-y on a like-for-like basis (ie ex Amicus and PVS acquisitions, Cardiff site closure and discontinued glass operations). This is likely to reflect some pricing improvement and, implicitly, volume softness, in our view. Given previous restructuring actions, progress from window systems (we expect, including weak competitor effects) and acquisitions, H119 EBIT should exceed its prior year equivalent (this was originally reported as £7.1m, like for like; likely to be slightly higher stripping out the exited glass business). Interim gains would support our assertion that despite still weak UK markets, FY18 represented the trough earnings year for Epwin. At the end of H119, net debt to EBITDA is understood to have been c 1x, slightly above the year-end position after the c £3m acquisition consideration is paid.
New facility investment and banking re-set
A site purchase, construction and lease agreement for a new warehouse and finishing facility at Telford has been signed, which will consolidate four other small facilities nearer to existing extrusion and fabrication operations. In financial terms, this yields a one-off £8m cash benefit for Epwin, which we expect to be received prior to the year-end. This is now in our model; there is no FY19 P&L effect and we will adjust as necessary (ie interest benefit, lease costs) for future years when H119 results are announced. Epwin has also re-set its banking arrangements with an enlarged RCF of £65m (previously c £60m spread across an RCF, term loan and accordion) and an overdraft facility of £10m (previously £5m) to 2022. This happened earlier than strictly required but simplifies Epwin’s financing structure.
Valuation: Value and income attractions
Epwin’s share price is back to levels seen at the beginning of the year following a c 13% decline since the beginning of June. (In contrast the FTSE All Share Index is up c 9% ytd.) As a result, the FY19 P/E of 7.3x and prospective dividend yield of 6.8% should appeal to value and income-focused investors alike. We acknowledge soft and uncertain markets but internal actions are driving our expectations of progress.
Exhibit 1: Financial summary
£m |
2013 |
2014 |
2015 |
2016 |
2017 |
2017 |
2018 |
2019e |
2020e |
2021e |
|||
December |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
|||
PROFIT & LOSS |
|
|
|
|
|
|
|
Restated |
|
|
|
|
|
Revenue |
|
|
255.3 |
259.5 |
256.0 |
293.2 |
298.3 |
292.8 |
281.1 |
291.3 |
296.2 |
300.9 |
|
Cost of Sales |
|
|
(185.8) |
(186.7) |
(178.6) |
(200.6) |
(207.5) |
(201.5) |
(196.4) |
(203.3) |
(206.8) |
(210.0) |
|
Gross Profit |
|
|
69.5 |
72.8 |
77.4 |
92.6 |
90.8 |
91.3 |
84.8 |
88.0 |
89.5 |
90.9 |
|
EBITDA |
|
|
21.4 |
24.5 |
25.6 |
33.3 |
30.3 |
32.1 |
27.0 |
28.2 |
29.5 |
30.3 |
|
Operating Profit (pre GW and except.) |
15.6 |
19.5 |
20.1 |
25.6 |
22.3 |
24.2 |
18.7 |
19.7 |
20.7 |
21.3 |
|||
Intangible Amortisation |
|
|
(1.7) |
(1.7) |
(0.0) |
(1.1) |
(1.1) |
(1.1) |
(1.2) |
(0.5) |
(0.5) |
(0.5) |
|
Exceptionals |
|
|
(5.1) |
2.3 |
(0.6) |
(0.2) |
(7.4) |
(7.4) |
(2.0) |
(0.5) |
0.0 |
0.0 |
|
Other |
|
|
0.0 |
(0.8) |
(0.4) |
(0.3) |
(0.6) |
(0.6) |
(0.7) |
(0.7) |
(0.7) |
(0.7) |
|
Operating Profit |
|
|
8.8 |
19.3 |
19.1 |
24.0 |
13.2 |
15.1 |
14.8 |
18.0 |
19.5 |
20.1 |
|
Net Interest |
|
|
(1.0) |
(0.7) |
(0.5) |
(1.0) |
(1.2) |
(1.2) |
(1.5) |
(1.4) |
(1.3) |
(1.2) |
|
Profit Before Tax (norm) |
|
|
14.6 |
18.0 |
19.2 |
24.3 |
20.5 |
22.4 |
16.5 |
17.6 |
18.7 |
19.4 |
|
Profit Before Tax (statutory) |
|
|
7.9 |
18.6 |
18.6 |
23.0 |
12.0 |
13.9 |
13.3 |
16.6 |
18.2 |
18.9 |
|
Tax |
|
|
(1.3) |
(3.5) |
(3.3) |
(3.4) |
(1.9) |
(2.3) |
(2.5) |
(3.2) |
(3.4) |
(3.5) |
|
Profit After Tax (norm) |
|
|
12.4 |
14.4 |
15.9 |
20.9 |
17.6 |
19.1 |
14.0 |
14.4 |
15.3 |
15.9 |
|
Profit After Tax (statutory) |
|
|
5.1 |
15.1 |
15.3 |
19.6 |
10.1 |
11.6 |
10.8 |
13.4 |
14.8 |
15.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average Number of Shares Outstanding (m) |
|
122.3 |
128.0 |
135.2 |
141.5 |
142.6 |
142.6 |
142.9 |
142.9 |
142.9 |
142.9 |
||
EPS - normalised (p) |
|
|
10.1 |
11.2 |
11.8 |
14.8 |
12.4 |
13.4 |
9.8 |
10.1 |
10.7 |
11.1 |
|
EPS - normalised (p) FD |
|
|
10.1 |
11.2 |
11.7 |
14.7 |
12.4 |
13.4 |
9.8 |
10.1 |
10.7 |
11.1 |
|
EPS - statutory (p) |
|
|
4.2 |
11.8 |
11.3 |
13.8 |
7.1 |
7.1 |
4.1 |
9.4 |
10.4 |
10.8 |
|
Dividend per share (p) |
|
|
0.0 |
4.2 |
6.4 |
6.6 |
6.7 |
6.7 |
4.9 |
5.0 |
5.3 |
5.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Margin (%) |
|
|
27.2 |
28.1 |
30.2 |
31.6 |
30.4 |
31.2 |
30.2 |
30.2 |
30.2 |
30.2 |
|
EBITDA Margin (%) |
|
|
8.4 |
9.4 |
10.0 |
11.3 |
10.2 |
11.0 |
9.6 |
9.7 |
9.9 |
10.1 |
|
Operating Margin (pre GW and except.) (%) |
6.1 |
7.5 |
7.9 |
8.7 |
7.5 |
8.3 |
6.7 |
6.7 |
7.0 |
7.1 |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE SHEET |
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed Assets |
|
|
54.7 |
53.8 |
93.5 |
108.5 |
106.2 |
|
111.7 |
115.9 |
115.6 |
115.1 |
|
Intangible Assets |
|
|
26.4 |
24.7 |
59.7 |
70.2 |
69.6 |
|
73.7 |
75.2 |
74.7 |
74.2 |
|
Tangible Assets |
|
|
25.1 |
26.2 |
33.1 |
37.9 |
36.0 |
|
37.3 |
40.0 |
40.2 |
40.2 |
|
Other |
|
|
3.2 |
2.9 |
0.7 |
0.4 |
0.6 |
|
0.7 |
0.7 |
0.7 |
0.7 |
|
Current Assets |
|
|
62.1 |
62.3 |
87.2 |
82.6 |
82.2 |
|
75.7 |
80.9 |
83.6 |
97.2 |
|
Stocks |
|
|
21.7 |
22.4 |
23.6 |
28.2 |
29.6 |
|
29.2 |
32.2 |
33.3 |
33.8 |
|
Debtors |
|
|
40.1 |
37.6 |
41.5 |
41.4 |
45.3 |
|
40.4 |
42.6 |
44.2 |
45.2 |
|
Cash |
|
|
0.3 |
2.3 |
22.1 |
13.0 |
7.3 |
|
6.1 |
6.1 |
6.1 |
18.2 |
|
Current Liabilities |
|
|
(54.5) |
(49.0) |
(68.8) |
(79.2) |
(79.2) |
|
(69.3) |
(76.6) |
(71.4) |
(76.7) |
|
Creditors |
|
|
(51.5) |
(48.6) |
(53.2) |
(62.9) |
(58.2) |
|
(63.7) |
(74.2) |
(75.2) |
(76.7) |
|
Short term borrowings |
|
|
(3.0) |
(0.4) |
(15.6) |
(16.3) |
(21.0) |
|
(5.6) |
(2.4) |
3.8 |
0.0 |
|
Long Term Liabilities |
|
|
(25.7) |
(4.3) |
(31.8) |
(21.0) |
(15.5) |
|
(28.1) |
(23.8) |
(23.8) |
(23.8) |
|
Long term borrowings |
|
|
(16.0) |
(0.8) |
(20.9) |
(17.3) |
(11.4) |
|
(25.3) |
(21.0) |
(21.0) |
(21.0) |
|
Other long term liabilities |
|
|
(9.7) |
(3.5) |
(10.9) |
(3.7) |
(4.1) |
|
(2.8) |
(2.8) |
(2.8) |
(2.8) |
|
Net Assets |
|
|
36.6 |
62.8 |
80.1 |
90.9 |
93.7 |
|
90.0 |
96.4 |
104.0 |
111.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOW |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Cash Flow |
|
|
12.1 |
19.8 |
23.8 |
30.8 |
19.9 |
18.1 |
25.8 |
23.4 |
26.8 |
29.4 |
|
Net Interest |
|
|
(0.9) |
(0.7) |
(0.5) |
(1.0) |
(1.0) |
(1.0) |
(1.3) |
(1.4) |
(1.3) |
(1.2) |
|
Tax |
|
|
(0.9) |
(1.7) |
(2.3) |
(3.8) |
(2.7) |
(2.7) |
(2.6) |
(2.7) |
(2.9) |
(3.0) |
|
Capex |
|
|
(4.9) |
(5.6) |
(9.0) |
(12.7) |
(7.1) |
(5.3) |
(12.5) |
(1.3) |
(9.3) |
(9.3) |
|
Acquisitions/disposals |
|
|
(0.2) |
0.0 |
(20.9) |
(10.2) |
(3.9) |
(3.9) |
0.0 |
(2.8) |
0.0 |
0.0 |
|
Financing |
|
|
0.0 |
10.0 |
0.0 |
0.0 |
0.0 |
0.0 |
(0.0) |
0.0 |
0.0 |
0.0 |
|
Dividends |
|
|
0.0 |
(1.9) |
(6.7) |
(9.1) |
(9.5) |
(9.5) |
(8.8) |
(7.0) |
(7.2) |
(7.6) |
|
Net Cash Flow |
|
|
5.2 |
19.9 |
(15.6) |
(6.1) |
(4.3) |
(4.3) |
0.5 |
8.2 |
6.2 |
8.3 |
|
Opening net debt/(cash) |
|
|
23.2 |
18.7 |
(1.1) |
14.4 |
20.6 |
20.6 |
25.1 |
24.8 |
17.3 |
11.1 |
|
Finance leases initiated |
|
|
(0.5) |
(0.3) |
0.4 |
1.9 |
(1.4) |
(1.4) |
(1.1) |
(0.7) |
0.0 |
0.0 |
|
Other |
|
|
(0.1) |
0.2 |
(0.3) |
(2.1) |
1.2 |
1.2 |
0.9 |
0.0 |
0.0 |
0.0 |
|
Closing net debt/(cash) |
|
|
18.7 |
(1.1) |
14.4 |
20.6 |
25.1 |
25.1 |
24.8 |
17.3 |
11.1 |
2.8 |
|
Source: Epwin accounts, Edison Investment Research. Note: FY13 to FY17 EPS benefited in part from recovered tax losses. FY17 restated for discontinued operations.
|
|
Research: Healthcare
Photocure announced results for Q219, with 23% revenue growth for the Hexvix/Cysview franchise (vs Q218) to NOK52.1m. Sequentially, however, Hexvix/Cysview sales only grew 2% due to lower Nordic and partner region revenues, which offset strong US sales. In the US, sales increased 52% over the same quarter in the previous year and 16% sequentially. This was driven mainly by improved reimbursement and a higher installed base of blue light cystoscopes. There are now 188 installed cystoscopes in the US, indicating 10% growth in the installed base over the quarter.